H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience (LEXX) shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as planned. The GLP-1-H24-4 study includes four planed DehydraTECH formulation arms and one Rybelsus comparator control arm and is slated to enroll 20 20 overweight, obese, pre- or type 2 diabetic patients for each of arms 1-4 at seven clinical sites, with the DehydraTECH-tirzepatide Arm 5 to be added at a later date if supported by positive results from the separate ongoing study GLP-1- H24-3, the analyst tells investors in a research note. Positive results from this study could expand the application of the DehydraTECH delivery technology in the GLP-1 sector, the firm says.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEXX:
- Lexaria Bioscience Initiates Promising Drug Study
- Lexaria Bioscience begins dosing for GLP-1 study #4
- Lexaria Bioscience Bolsters Drug Delivery Strategy
- Lexaria Bioscience forms Scientific Advisory Board
- Lexaria Bioscience Welcomes New Chief Medical Advisor
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
